Abstract: The polycystic ovary syndrome is an extremely common endocrine disorder in women of childbearing age. It is characterized by menstrual disturbance, hyperandrogenism and/or hyperandrogenemia. The primary pathophysiological defect is unknown, but important characteristics include insulin resistance, androgen excess and impaired gonadotropin dynamics. The most frequent clinical characteristics of polycystic ovary syndrome are associated with the pilosebaceous unit, such as hirsutism, acne, seborrhoea and alopecia. Thus, the dermatologist may be responsible for making an early diagnosis of the syndrome, thus preventing delay in establishing preventive and therapeutic measures. The current management recommended for skin manifestations of polycystic ovary syndrome includes combined oral contraceptives, antiandrogens and insulin-sensitizing agents, besides changes in life style. This is a review article on diagnosis, pathophysiology and treatment of polycystic ovary syndrome. The authors emphasize that a clear understanding of pathophysiology of this syndrome, especially by dermatologists, is crucial for its preventive treatment through the different phases in the life of women.

Keywords: Hyperandrogenism / diagnosis; Hyperandrogenism / therapy; Skin; Insulin resistance; Hypothalamic-pituitary axis; Treatment

Resumo: A síndrome do ovário policístico é distúrbio endócrino feminino, extremamente comum na idade reprodutiva. Caracteriza-se por anormalidades menstruais, hiperandrogenismo e/ou hiperandrogenemia. A principal alteração na fisiopatologia é desconhecida. Entretanto, parece que a resistência à insulina, o hiperandrogenismo e a alteração na dinâmica das gonadotropinas são os mais importantes mecanismos fisiopatológicos envolvidos. As características clínicas mais freqüentes da síndrome do ovário policístico estão relacionadas com a unidade pilossebácea, como bêriscutismo, acne, seborrêia e alopecia. Desse modo, o dermatologista pode ser responsável pelo diagnóstico precoce da síndrome, evitando o retardo na instituição de medidas terapêutico-preventivas. Atualmente, as drogas recomendadas para as manifestações cutâneas da síndrome do ovário policístico são os contraceptivos orais conjugados, antiandrógenos e sensibilizantes de insulina e, além disso, é geralmente recomendada a modificação no estilo de vida. Trata-se de artigo de revisão sobre diagnóstico, fisiopatologia e tratamento da síndrome do ovário policístico. Os autores enfatizam que o conhecimento da fisiopatologia dessa síndrome, principalmente pelos dermatologistas, é fundamental para seu tratamento preventivo, nas diferentes fases da vida da mulher.

Palavras-chave: Hiperandrogenismo / diagnóstico; Hiperandrogenismo / terapia; Pele; Resistência à insulina; Sistema hipotálamo-hipofisário
INTRODUCTION

Hyperandrogenism is a term used to describe the clinical signs related to the biological action of androgens. Hyperandrogenemia or biochemical hyperandrogenism means increased blood androgen levels. The maximum clinical expression of hyperandrogenism is virilization. Idiopathic hyperandrogenism is characterized by clinical expression and no biochemical alterations, whereas occult hyperandrogenism is characterized by no clinical expression and presence of biochemical changes.

Hyperandrogenism leads to clinical pictures of variable severity in females, including early puberty, hirsutism, acne, seborrhea, alopecia, menstrual disturbance and ovulatory dysfunction in infertility during reproductive life, metabolic syndrome, psychological disorders and virilization. The intensity and extension of these clinical manifestations depend on several factors, and there is no strict correlation between intensity of clinical picture and biochemical alterations.

Several etiologies may cause hyperandrogenism in women, ranging from hormone disorders in the ovaries and adrenal glands (polycystic ovary syndrome - PCOS and non-classical congenital adrenal hyperplasia - NCAH) to ovarian or adrenal cancer.

The main form of hyperandrogenism in females is functional ovarian or PCOS, which accounts for two-thirds of hyperandrogenic women, and approximately 50% of PCOS cases present functional adrenal hyperandrogenism.

PCOS has a very heterogeneous clinical picture and is the most common endocrinopathy in women of childbearing age, with a prevalence of 6% to 10%. It is characterized by clinical and/or biochemical hyperandrogenism and menstrual irregularities, and it is probably the most frequent cause of hirsutism and infertility. The etiopathogenesis is still unknown, although several associations with biochemical abnormalities have been described.

Stein, Leventhal were the first investigators to identify the association of enlarged and polycystic ovaries and amenorrhea, hirsutism and obesity. PCOS was associated with adrenal hyperplasia and, later, with hyperinsulinemia, thus demonstrating its metabolic and reproductive effects. Other investigators observed later that the defect was in insulin receptors and obese and non-obese women presented hyperinsulinemia. From then on, the association between hyperandrogenism, hyperinsulinemia and alterations in serum lipid levels was given special attention for being able to change the prognosis of PCOS.

Many factors contribute to making diagnosis of PCOS difficult. The National Institute of Child Health & Human Development (NIHD/NICHD) considered the following diagnostic criteria for PCOS: presence of chronic anovulation, hyperandrogenism and/or hyperandrogenemia and ruling out other endocrine diseases with similar phenotype. The European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine (ESHRE/ASRM) recommended, apart from ruling out other conditions, the presence of two out of three criteria, as follows: 1) menstrual dysfunction with oligo-ovulation or anovulation, 2) hyperandrogenism or hyperandrogenemia and 3) presence or not of polycystic ovaries.

In principle, the early diagnosis of PCOS is important for the possibility of preventing the development of some diseases associated with the syndrome. Thus, dermatologists may be responsible for making such diagnosis due to the skin manifestations of hyperandrogenism. The objective of this review is to provide an update on pathophysiology, diagnosis and treatment of PCOS, considering that, in the past 10 years, the pathophysiological and therapeutic aspects have been correlated, particularly regarding peripheral insulin resistance.

HYPOTHALAMUS-PITUITARY-OVARY-ADRENAL AXIS - ANDROGEN BIOSYNTHESIS, FACTORS RELATED TO ITS PRODUCTION AND THE ROLE OF INSULIN

1. Hypothalamus-pituitary-ovary-adrenal axis

The hypothalamus and the pituitary gland are the structures that regulate the endocrine system. The sensorial and endocrine information is processed and integrated in the brain, by means of connections between the pituitary gland and hypothalamic or portal system neurons. In the pituitary anterior lobe, the portal system produces peptides that bind to specific cell membrane receptors, thus initiating hormone release (HR) or inhibition (HI) of anterior pituitary hormones. The hypothalamus stimulates the production of gonadotropins in the pituitary through pulsatile gonadotropin-release hormone (GnRH), increasing
the transcription of gonadotropin genes (luteinizing hormone - LH and follicle-stimulating hormone - FSH) (Figure 1A).27,28 Hence, the frequency of pulsatile GnRH stimulus partly determines the relative proportion LH and FSH synthesis.27 The increased frequency of GnRH pulse favors the transcription of LH β-subunit over FSH; conversely, decreased GnRH pulse frequency favors the transcription of FSH β-subunit, reducing the transcription rate of LH over FSH.27,28

2. Androgen biosynthesis and factors related to its production
The androgens derive from cholesterol and, in females, are synthetized by the ovaries, adrenal glands and in extraglandular sites of steroid conversion (liver, muscles, skin and adipose tissue).29,30 Androgen aromatization occurs in muscle and adipose tissues, that is, testosterone (T) and androstenedione (A) are converted into estrogens - estrone and estradiol, whereas, in the pilosebaceous unit and skin, T is converted into dihydrotestosterone (DHT) by the enzyme 5-alpha-reductase 1 or 2 (Figure 1B).29

The pilosebaceous unit and skin represent target-structures for androgen, which explains the pathophysiology of hyperandrogenism cutaneous manifestations (hirsutism, acne, seborrhea and alopecia).2

3-alpha-androstenediol glucuronide (3α diol G) derives from the conversion of DHT and A, by means of 5α-reductase. It is considered a marker of androgen biological action in the pilosebaceous unit, and the skin its main production site.2,4,29,30

Androgen biosynthesis (Figure 2) is mediated by cytochrome P-450c-17, an enzyme with 17α-hidroxylase, 17, 29-lyase and 17β-hydroxysteroid dehydrogenase (17β HSD or 17β R) activities. The androgens (A and T) are aromatized to estrone by the enzyme aromatase (cytochrome p-450 aromatase).27,29,31

In the ovaries, the androgens are precursors of estrogens and their production is controlled by
Normal ovarian function is determined by a combined action of LH in the theca cells, corpus luteum and stroma, and of FSH in granulosa cells. FSH stimulates the synthesis of estrogens, inhibin, activin and follistatin in granulosa cells. 

Eighty percent of circulating T is bound to a protein produced by the liver - β-globulin (SHBG), 19% is bound to albumin, and only 1% is free and responsible for the peripheral effect of androgens.

Increased levels of β-globulin are related to higher levels of estrogens and thyroid hormones, while androgens, obesity, glucocorticoids, growth hormone (GH) and insulin inhibit its synthesis.

Androgen binding to androgen receptors (AR) is related to DNA, production of mRNA and of enzyme proteins required for its action (Figure 1B).

**3. The role of insulin**

Insulin is a polypeptide secreted by β-cells of the pancreas, and play an important role in glucose homeostasis. The classic target tissues include liver, muscles and adipose tissue. The terms insulin sensitivity and insulin resistance (IR) refer to the action of insulin in glucose homeostasis.

**PATHOPHYSIOLOGY OF THE PCOS**

The heterogeneity of PCOS reflects the participation of multiple pathophysiological mechanisms (Figure 3); however, how much each mechanism contributes to developing PCOS is still unknown.

Biochemical abnormalities were described and it seems that the primary defect is IR in muscles and adipose tissue, associated with compensatory...
Hyperandrogenism and skin: polycystic ovary syndrome...


hyperinsulinemia although the ovaries remain sensitive to insulin. Furthermore, IR may be related to an intrinsic dysfunction of pancreatic β-cells.

The genetic etiology may be observed in mothers and sisters of PCOS patients, mainly because of higher frequency of the syndrome and IR. Nevertheless, the mode of inheritance remains uncertain and unknown, as well as the influence of several environmental factors, such as diet and lifestyle.

Another important characteristic in PCOS is changes in gonadotropin metabolism. In vivo and in vitro studies (thecal cell culture) in women with PCOS suggested that thecal cells are more efficient to convert androgen precursors into T than normal cells. The capacity of these cells to increase production of androgen is intrinsic and it might be genetically determined. Other in vivo studies observed abnormalities in the granulose cells of PCOS patients.

The theories proposed to explain the pathophysiology of PCOS could be divided into four categories:

a) single defect in action and secretion of insulin, causing hyperinsulinemia and IR;

b) primary neuroendocrine defect, leading to increased pulse frequency and amplitude of LH;

c) defect in androgen synthesis, resulting in increased production of ovarian androgens; and

d) alteration in cortisol metabolism, resulting in increased production of adrenal androgens.

1. Hyperinsulinemia and IR

Hyperinsulinemia is believed to be a biochemical, central and, probably hereditary alteration of PCOS (Figure 4). In 1980, the association between hyperandrogenism, insulin resistance and acanthosis nigricans was identified (Hairan syndrome). Since then IR has been the best biochemical correlation for acanthosis nigricans.

Insulin may act through insulin receptors, which are distributed in the ovaries, through IGF-1 receptors or even by means of hybrid receptors that contain a combination of α and β subunits of insulin and IGF-1 receptors. Apparently there is a hereditary genetic predisposition in post-receptor mechanisms.

---

**Figure 2**: Steroidogenesis. Model of androgen biosynthesis in the ovaries and adrenal glands

**Chart 2**: Percentage of androgen production by the ovaries and adrenal glands

<table>
<thead>
<tr>
<th>Hormones</th>
<th>Ovaries (50%)</th>
<th>Adrenal glands (50%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Androstenedione</td>
<td>50%</td>
<td>50%</td>
</tr>
<tr>
<td>Total testosterone</td>
<td>5-20%</td>
<td>0-30%</td>
</tr>
<tr>
<td>DHEA</td>
<td>1-10%</td>
<td>90%</td>
</tr>
<tr>
<td>SDHEA</td>
<td>5%</td>
<td>95%</td>
</tr>
</tbody>
</table>

Sources: Spinedi E et al, Perez Gutierrez JF et al.
• Androgen excess in PCOS may be ovarian and/or adrenal and, consequently, increased biosynthesis of ovarian androgens results in abnormalities in the whole hypothalamus-pituitary-ovary axis.

• The peripheral increase in cortisol metabolism, due to impaired 5α-reductase and/or 11-beta hydroxylase activity, may lead to PCOS. However, in women with PCOS, the cause of this alteration remains unknown.

Sources: American Association of Clinical Endocrinologists, Rosenfield RL, The Rotterdam ESHRE/ASRM et al.

Paulo Matarazzo Júnior
Department of Endocrinology
University of São Paulo School of Medicine
São Paulo
Brazil

Adipose tissue
Extraglandular aromatization

Hypothalamus
secretion LH
secretion FSH

Ovary
Stimulus in stroma and theca

Stimulus in stroma
and theca

Adrenal
Androgen excess

ovarian androgen
secretion

Chronic
anovulation

Follicle maturation

Plasma FSH

Plasma LH

estrone

5α-reductase activity (liver)
11β HSD1 activity (liver and adipose tissue)

Cortisol metabolism

ACTH

Obesity

Adrenal androgens (normal plasma cortisol)

FIGURE 3: Pathophysiology of PCOS

Abdominal obesity
Family history of type 2 DM
Genetic predisposition - SOPC
Ageing
Pregnancy
Drugs (corticosteroids, thiazide diuretics and danazole)
Way of life (physical deficiency of exercise, smoker)

Changes cholesterol and lipoprotein metabolism

SHBG
IGBP-I

Free testosterone
estradiol
IGF-I

Insulin resistance
yperinsulinemia

In the pathogenesis of hyperandrogenism of PCOS, insulin may have a direct and/or indirect mode of action.

DM - diabetes mellitus, P450c-17 - cytochrome, 11 HSD1 - 11 hydroxylase

PCOS therapy

new target

traditional target

Sources: Kidson W, Tsilchorozidou T

FIGURE 4: Peripheral insulin resistance and PCOS
of insulin, for many obese and insulin-resistant women do not develop PCOS.19,46

The tyrosine-kinase insulin receptors include IGF-1, epidermal growth factor, fibroblast growth factor, platelet-derived growth factor, colony-stimulating factor-1 and several cytokine receptors.18,19 The factor that induces phosphorylation of serin in insulin receptor and in cytochrome P450-c17α seems to be a protein-kinase, which causes IR and hyperandrogenism, respectively. The factor responsible for serin phosphorylation is genetically determined. Therefore, the genetic defect in serin phosphorylation could explain the association of PCOS and IR.19,24 Hyperinsulinemia increases the production of androgens in the ovaries and of IGFs in the liver.37,39 The direct effect of insulin and IGF-1 is increased 17-hydroxilase activity in the ovaries, causing an excessive production of androgens, particularly A and T and its precursor, 17-hydroxyprogesterone (17-OHP).46 IGF-1 inhibits the enzyme aromatase and hence prevents the conversion of T into estrogens.47 Indirectly, insulin seems to potentize the action of LH in the ovaries.48 Another effect of hyperinsulinemia, and similar to obesity, is to decrease the hepatic production of SHBG, the protein that carries the sexual hormone sexual, and of IGFBP-1, the protein that carries IGF-1 or IGF binding protein-1, thus contributing to a broader action of free testosterone (FT) and IGF-1, respectively in target-cells.35,49

Glucose, leptin and lipid intolerance

PCOS is a risk factor more important for glucose intolerance than race ethnicity.24 The association between PCOS and gestational diabetes (type 1 and 2) in families is controversial.50,51

Leptin seems to have a direct effect in ovarian steroidogenesis due to the presence of leptin receptors in thecal and granulose cells; moreover, granulose cells are able to synthesize leptin (Figure 1A).52,54 Peripheral insulin resistance probably accounts for reduction in leptin53 and resistin56 concentration in the adipocytes of women with PCOS.

In PCOS, total cholesterol is increased because of raised low-density lipoprotein (LDL); however, high-density lipoprotein (HDL) is decreased. Blood levels of triglycerides are elevated, as well as plasminogen activator inhibitor (PAI). The increase in PAI levels and alteration in lipid levels seem to be responsible for the increased incidence of hypertension, coronary artery disease and thrombosis in PCOS.57

2. Defect in the neuroendocrine system

By and large, the inappropriate secretion of gonadotropins is associated to the classical PCOS. The increased secretion of gonadotropins is related to increased activity of GnRH pulse generator and to pituitary response to GnRH. LH and FSH synthesis and secretion depend on GnRH stimulus, which is characterized by fast and slow frequencies that, respectively, favor their secretion.58 Deregulation of the mechanism of GnRH secretion is still not clear. Through observations in the peripubertal period (adrenarche) in females, it was suggested that changes in neuronal system information caused by insulin, IGFs (IGF1 and IGF2) and sexual steroids could induce deregulation of GnRH pulse generator.52,59 The weak peripheral aromatization of the androgen from A and estrone concentration may increase pituitary sensibility to GnRH by direct action in the synthesis of gonadotropins, as well as sensibility of GnRH receptors,59 thus contributing to pathogenesis of PCOS and justifying the increased LH levels and the excessive response of LH to GnRH. Marshall et al.56 observed some abnormalities in the function of hypothalamic neurotransmitters.56 However, it is still not clear if these neurotransmitters play any role in the pathophysiology of PCOS. In the polycystic ovary syndrome, during the follicular phase, there is a disproportion of gonadotropins, that is, LH pulsatile secretion is increased and that of FSH is reduced.60 The increase in the LH/FSH ratio57 from 2:1 to 3:1 indicates the abnormal secretion of gonadotropins.54,65

3. Defect in ovarian steroid synthesis

PCOS patients present an increase in GnRH48 and LH41 pulse frequency and, consequently, in ovarian androgen synthesis.28,29,58-63 It is still unknown if increased GnRH pulse frequency is due to intrinsic abnormalities in GnRH pulse generator or if it is caused by relatively low levels of progesterone, resulting in anovulatory cycles (Figure 3).28,29

Some studies carried out on thecal cell cultures suggest that these cells, in PCOS, are more efficient to convert androgen precursors into T than the normal cells,29 and there is also deregulation in ovarian steroidogenesis due to changes in the enzymes 17-hydroxylase and 17, 29-lyase, that is, in cytochrome

---

* The obese individuals present leptin resistance.52,53
** Dopamine, opioids and the alpha-adrenergic system.
*** The prevalence of increase in this ratio ranges from 30% to 90%. Such variability is due to the number and interval of samples collected and to specificity of gonadotropins. The gene responsible for specificity is in LH b-subunit, and mutations in this subunit might be associated with gonadal dysfunction and infertility.42-45

---

P450c of thecal cells. Moreover, the synergic effect of hyperinsulinemia and the increase in IGF must be considered.

In women suffering from PCOS, follistatin levels are elevated and activin levels are lower than in non-PCOS women. The peripheral metabolism of steroids is altered in PCOS, primarily in adipose and muscular tissues and in the pilosebaceous unit. Hence, hirsutism, acne, seborrhea and alopecia are common and reflect hyperandrogenism, which may be progressive or not.

The adipose tissue is able to form T and estrogen from inactive precursors, contributing to increased steroid levels. In the pilosebaceous unit, there is an increase in activity of the enzyme 5α-reductase, converting T into DHT. The activity of 5α-reductase is mediated by IGF-1 and may be intensified by hyperinsulinemia, thus aggravating hirsutism.

Insulin seems to have a direct and stimulating effect in the pilosebaceous unit (hirsutism, acne, seborrhea and alopecia) and in the epidermis (acanthosis nigricans).

**4. Peripheral increase in cortisol metabolism**

Increased androgen production by adrenal glands is observed in 25% of PCOS patients, probably as a result of genetic influence or secondary to abnormal secretion of ovarian androgens.

**GENETICS OF PCOS**

PCOS is believed to be hereditary; however, the mode of inheritance is unknown. The several genes proposed and investigated as the main and possibly PCOS-related genes include those that regulate the hypothalamus-pituitary-ovary axis and those associated with peripheral insulin resistance and its sequelae. New genes have been identified and are related to insulin and gonadotropin action and secretion, and androgen biosynthesis, secretion, transport and metabolism, contributing to the heterogeneous phenotype of this syndrome.

**CLINICAL PICTURE AND DIAGNOSIS OF PCOS**

The clinical picture (Chart 3) and the heterogeneous hormone profile, the multifactorial theory of its pathogenesis and lack of consensus as to definition of PCOS represent the factors that contribute to making its diagnosis difficult.

According to the last consensus, PCOS could be diagnosed after ruling out other diseases that cause irregular menstrual cycles and androgen excess (Figure 5, Chart 4), by means of identifying at least two of the following criteria: oligo-ovulation or anovulation, which is usually manifested with oligomenorrhea or amenorrhea; increased androgen levels in blood (hyperandrogenemia) or clinical manifestations of androgen excess (hyperandrogenism); and ovary cysts defined by ultrasonography (10 or more cysts measuring 2-8mm).

PCOS is a chronic condition that has clinical manifestations clinical at any age and not only in...
The complementary exams required for PCOS investigation are basically ultrasound and hormone levels.\textsuperscript{2,9,7}

1. Ultrasonography

It should be performed between day 25 of the current menstrual cycle and day 3 of the next period. Transvaginal, rather than abdominal, ultrasound is recommended for providing better visualization.\textsuperscript{2,61}

2. Hormones

General orientations

a) Collect blood in the morning (8h), in the first week of the regular menstrual cycle.\textsuperscript{23}

Plasma hormone levels

a) 17-OHP - it is important to perform this test...
### CHART 4: Differential diagnosis of PCOS

<table>
<thead>
<tr>
<th>Disease</th>
<th>Hiperandrogenism and/or hyperandrogenemia</th>
<th>Oligomenorrhea or amenorrhea</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCCAH (21- hydroxylase deficiency)</td>
<td>Yes</td>
<td>Often absent</td>
<td>Family history of hirsutism and/or infertility</td>
</tr>
<tr>
<td>Cushing's syndrome</td>
<td>Yes</td>
<td>Present</td>
<td>Hypertension, striae</td>
</tr>
<tr>
<td>Hyperprolactenemia or prolactinoma</td>
<td>No or moderate</td>
<td>Present</td>
<td>Galactorrhea</td>
</tr>
<tr>
<td>Primary hypothyroidism</td>
<td>No or moderate</td>
<td>May be present</td>
<td>Weakness, menstrual disturbances, xeroderma, alopecia, weight gain and goiter</td>
</tr>
<tr>
<td>Adrenal virilization or ovarian neoplasm</td>
<td>Yes</td>
<td>Present</td>
<td>↑ clitoris, severe hirsutism, androgenetic alopecia</td>
</tr>
</tbody>
</table>

↑ - increase, ↓ - decrease.

**Source:** Ehrmann DA

### CHART 5: Diagnostic criteria for metabolic syndrome

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal obesity (waist circumference)</td>
<td>&gt;88cm</td>
</tr>
<tr>
<td>Triglycerids</td>
<td>≥150mg/dL</td>
</tr>
<tr>
<td>HDL</td>
<td>&lt;50mg/dL</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>≥130/≥85mm Hg</td>
</tr>
<tr>
<td>Fasting glucose and glucose tolerance test (two hours), insulinemia</td>
<td>Fasting glucose =110-126mg/dL and/or insulinemia</td>
</tr>
</tbody>
</table>

**Source:** The Rotterdam ESHRE/ASRM et al

- The analysis of only one criterion for IR should not be used for IR individuals
- HDL - high density lipoprotein. Metabolic syndrome is confirmed by three or four criteria

Other insulin resistance indexes:
- Índice de Homa-b (homeostasis model Assesment): 20x insulinemia (µUI/ml)/glycemia (mmol/L) · 3,5
  Normal range: 167 a 175.
- HOMA-r (Homeostasis Model Assesment): insulin (µUI/ml) x glycemia (mmol/L)/22,5. Normal range: 0,97-1
- Fasting glucose and insulin. Insulin resistance ≤ 4,5
  To change glycemia mg/dL into mmol/L: multiply by 0,05551.
in the morning because of corticotropin peak. In PCOS, 17-OHP levels may be normal or slightly increased.31 The plasma prolactin and 17-OHP levels are enough to rule out hyperprolactenemia and NCCAH due to 21-hydroxylase deficiency.

b) Prolactin - normal levels.31

c) FSH and LH - LH/FSH ratio is > 3:1.64
d) TT, FT and SHBG - the method recommended7 to calculate FT is by measuring TT and SHBG levels. FT levels are increased and SHBG levels are reduced. TT levels may be elevated or normal.2,9

e) Dehydroepiandrosterone DHEA and SDHEA - both in PCOS and NCCAH, the increase in SDHEA levels is lower than 7 µg/dL. In adrenal tumors, SDHEA is higher than 7µg/dL. DHEA is increased in NCCAH (Chart 2).7

f) 3-alpha diol G - it is a DHT metabolite produced in androgen-responsive tissues (for instance, hair follicle). It is raised in PCOS, idiopathic hirsutism and it is decreased in 5α-reductase deficiency.2

 g) Adrenocorticotropic hormone (ACTH) stimulation test. Cortrosyn® - 250ug IV- the test is performed to detect deficiency of several steroidogenesis enzymes in adrenal glands, mainly 21-hydroxylase deficiency.2 The test is indicated only for screening morning levels of 17-OHP with above normal concentrations or if there is any suspicion of enzyme deficiency. Plasma cortisol, 17-OHP, SDHEA and DHEA should be measured in the morning, before and 60 minutes after Cortrosyn® injection.2

h) GnRH stimulation test - it is conducted to confirm the ovarian origin of androgens. In PCOS investigation it is useful to identify the presence of 17-hydroxylase deficiency.7

i) Dexamethasone suppression test (Figure 5) - it is performed to differentiate functional adrenal hyperandrogenism (ACTH-dependent) from tumor adrenal hyperandrogenism (ACTH-independent). The test is indicated when TT is higher than 200ng/mL, and/or SDHEA is higher than 7µg/dL. Plasma cortisol, SDHEA and TT should be measured in the morning before and five days after the administration of dexamethasone (0.5mg, four times/day, at 6, 12, 18 and 24 hours).2,7

j) IR - several criteria have been suggested to assess IR (Chart 5):72-75

- fasting glucose,
- body mass index (BMI), IR with BMI ≥ 25kg m⁻²,
- glycemic index,
- glucose tolerance test - 2 hours after 75mg of glucose,
- fasting insulin - IR with insulinemia ≥ 17.3 UI/l in women,
- fasting glucose/insulin ratio,
- HOMA-r,
- HOMA-b analysis

k) as to lipid metabolism, it is recommended to measure total cholesterol total and its fractions (HDL and LDL) and triglycerids (Chart 5).2

TREATMENT

The choice of treatment in PCOS depends on the clinical and laboratory pictures. In Dermatology, the objective of treating PCOS is to reduce androgen levels,76 in order to attenuate their effects on skin and pilosebaceous units. Together with drug therapy, it is necessary to change life style, diet and to exercise.76

The therapeutical options for skin manifestations related to androgen excess include, as follows:

1. combined oral contraceptives: cyproterone acetate (2mg) + ethinyl estradiol (35 µg) for 21 days or drospirenone** (3mg) + ethinyl estradiol (30 µg) for 28 days. The antiandrogen effect is due to decreased LH and, consequently, reduced ovarian production of androgen by the estrogenic component.2 Estrogens also increase the synthesis of SHBG, thus reducing FT.2 The use of oral contraceptives requires special monitoring, that is, gynecologic and breast examination.2 The effectiveness of contraceptives is greater in acne (50%) and lower in hirsutism, which requires administration for longer periods.2,31,77 The adverse effects of contraceptives in IR, glucose tolerance, vascular reactivity and coagulability should be taken into account, particularly after availability of drugs that reduce insulin levels.78

2. antiandrogens: a) cyproterone acetate (25mg to 50mg, in the first 10 days of the cycle) - it is a potent progesterone with moderate antiandrogen action. It inhibits T and DHT binding to androgen receptor, reduces the concentration of 5α-reductase in the skin and decreases the secretion of

---

* The decrease in androgen levels may occur by inhibiting its production in the ovaries, by increased SHBG levels or blocking receptors in target tissues.

** Drospirenone is a spironolactone analogue.
ovarian androgens by inhibiting gonadotrofin release.² Hirsutism improves after a 3-to-6-month treatment.² The side effects include irregular uterine bleeding, nausea, vomiting, headache, fatigue, weight gain and reduced libido.²7²

b) spironolactone - it has a moderate antiandrogen effect when administered as a 100-
200mg/day dose. Shaw⁸⁰ published the following guidelines for spironolactone: initial dose of 25mg, twice a day; if well tolerated, increase to 50mg, twice a day; in case of no benefits after three months, higher doses should be considered. The duration of treatment could be extended and associated with combined oral contraceptives.

c) flutamide - potent nonsteroidal antiandrogen that is effective in treating hirsutism, but severe hepatocellular dysfunction has limited its use.⁵¹

d) finasteride - It is a 5α-reductase inhibitor that is given for hirsutism, 5mg/day, and patients improve after three-months⁸¹

d) eflornithine - inhibitor of the enzyme decarboxylase ornithine in human skin, it is available in creams for topical use. The primary action of the drug is to inhibit hair growth.⁸²

3. insulin-sensitizing agents: metformin, thiazolidinediones.⁵¹,⁷⁸ These agents enhance tissue sensitization to the action of insulin.

a) metformin* - Velásquez⁸⁵ published the first study on metformin in PCOS. Metformin reduces hepatic gluconeogenesis and increases muscle sensitization to insulin, decreasing serum insulin levels and thus reducing androgen production by thecal cells.⁸⁴ However, it is not a hypoglycemic agent because it does not increase insulin secretion.²⁸⁵ Moreover, metformin reduces total cholesterol, LDH and triglyceride levels, and increases HDL levels.⁸⁶,⁷⁷ Decreased androgen concentration caused by metformin is an effect still not clear.⁸⁴ Apparently it has direct influence in ovarian steroidogenesis, reducing androgen production.⁸⁴ The recommended dose is 500mg, 3x/day or 850mg, 3x/day. It is effective in treating anovulation in women with PCOS and, in long-term treatments it may improve hirsutism.⁸⁷ The most important side effects are gastrointestinal symptoms (diarrhea, nausea, vomiting, flatulence and anorexia), which occur in 30% of patients, decreased B12 vitamin levels in 6% to 9%, and metallic taste in 3%. The contraindications are renal disease, metabolic acidosis, congestive heart failure, and hypersensitivity to metformin. Avoid use of contrast medium containing iodine.²,⁸³,⁸⁴

b) thiazolidinediones (troglitazone, pioglitazone, rosiglitazone) - these are true insulin-sensitizing agents that are able to improve insulin action in the liver, skeletal muscles and adipose tissue.⁸⁵,⁸⁶ These drugs have the capacity to activate certain genes involved in fat synthesis in carbohydrate metabolism, thus improving IR, hyperandrogenemia and glucose tolerance.⁸⁵,⁸⁷ and they lead to less weight loss than other insulin-sensitizing agents.⁸⁸ Roziglitazone and pioglitazone are currently approved for use. Treatment with roziglitazone was associated with improved function of pancreatic β-cells and decrease in PAI.⁸⁵,⁸⁶

c) D-chiro-inositol - it was recently studied in PCOS patients. It is a pure substance called pinitol,” derived from pine trees.⁸⁹ The therapy with D-chiro-inositol, in obese women with PCOS improves insulin metabolism by acting in its receptors, decreasing serum insulin and androgen (FT) and increased SHBG) levels.⁸⁵,⁸⁹ The recommended dose is 1200mg/day.⁹⁰

The response to therapy with insulin-sensitizing agents is directly proportional to BMI, fasting insulin, total cholesterol and LDL-cholesterol and blood pressure, and inversely proportional to A and HDL levels.

CONCLUSION

PCOS is a complex disorder of unknown etiology, and it involves several specialists for presenting reproductive, endocrinologic, dermatological, gynecological, cardiac and psychological implications.

Hyperinsulinemia seems to be one of the main factors responsible for steroidogenesis deregulation.

The variable and heterogeneous clinical picture makes diagnosis of PCOS difficult and tends to delay management that could avoid late complications.

Its treatment is preventive and aims to maintain the endometrial healthy, to antagonize the actions of androgens in target-tissues, to reduce insulin resistance (IR) and to correct anovulation. In addition to combined contraceptives and antiandrogens, the insulin-sensitizing agents are effective in preventing diseases associated with hyperinsulinemia. It is difficult to explain the therapeutic

---

* It is a biguanide molecule.
** This drug is chemically defined as inositol.
success of metformin in reducing insulin and androgen levels, as observed in some studies. It may be related to genetic variations, body weight, lifestyle, duration of treatment and dosage of the drug. 

Today, in order to avoid late complications, the specialists share investigations, trying to understand the etiology and pathophysiology of PCOS, which are essential for its treatment. The main focus of these studies has been several genetic and environmental determinants of the syndrome, for reflecting its heterogeneous phenotype.

REFERENCES

Hyperandrogenism and skin: polycystic ovary syndrome...


Apter D, Butzow T, Laughlin GA, Yen SS. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J Clin Endocrinol Metab. 1995;80:2966-73.


Norman RJ, Milner CR, Groome NP, Robertson DM. Circulating follistatin concentrations are higher and activin concentrations are lower in polycystic ovarian syndrome. Hum Reprod. 2001;16:668-72.


Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:1273-6.

Legro RS, Finegood D, Dunaiil A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83:2694-8.


MAILING ADDRESS:
Samira Yarak
Departamento de Dermatologia
Unifesp - Escola Paulista de Medicina
Rua Botucatu, 740
04023-900 - São Paulo - SP
Tel./fax: +55 11 5571-2947
E-mail: sa.la@terra.com.br